2.0
11. Sept. 2014
Aktueller Mitarbeiter, mehr als 8 Jahre
New York, NY
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Very diversified company. Good exposure to both Life Sciences and Industrial business. Benefits in general are good but the endless cost cutting is taking a toll.
Kontras
Senior leadership's goals are clearly short term. Financial community seems to not notice the complete lack of a long term strategy. Benefits and resource cost cutting are being offset by excessive executive compensation.